Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer

BACKGROUND: Treatment options for patients with triple-negative breast cancer (TNBC) remain limited to mainstay therapies owing to a lack of efficacious therapeutic targets. Accordingly, there is an urgent need to discover and identify novel molecular targets for the treatment and diagnosis of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Fei, Huang, Jiajia, Zhu, Wancui, Jiang, Tongchao, Guo, Jia, Xia, Wen, Chen, Miao, Guo, Ling, Deng, Wuguo, Lin, Huanxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416624/
https://www.ncbi.nlm.nih.gov/pubmed/37575241
http://dx.doi.org/10.3389/fimmu.2023.1218987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416624/
https://www.ncbi.nlm.nih.gov/pubmed/37575241
http://dx.doi.org/10.3389/fimmu.2023.1218987

Ejemplares similares